 |
|
Apolipoprotein E  4 Count Affects Age at Onset of Alzheimer Disease, but Not Lifetime Susceptibility
The Cache County Study
Ara S. Khachaturian, PhD;
Christopher D. Corcoran, PhD;
Lawrence S. Mayer, MD;
Peter P. Zandi, PhD;
John C. S. Breitner, MD; for the Cache County Study Investigators
Arch Gen Psychiatry. 2004;61:518-524.
Background The incidence of Alzheimer disease (AD) increases strongly with age, but little is known about the cumulative incidence of AD over a lifetime of 100 years, or its relationship to the polymorphic APOE locus that encodes apolipoprotein E. APOE is a strong genetic risk factor for AD
Objectives To estimate the occurrence of AD as a function of age and number of APOE  4 alleles; and to explore evidence for heterogeneity of AD risk related toAPOE genotype and to other sources.
Design Nonparametric and parametric survival analyses of AD incidence in prospective longitudinal study.
Setting and Participants A total of 3308 elderly residents of Cache County, Utah.
Main Outcome Measures Cumulative incidence of AD; in mixture models assuming susceptible and nonsusceptible individuals, the proportion of individuals not susceptible to AD at any age.
Results Models that assumed a proportion of invulnerable individuals provided strongly improved fit to the data. These models estimated the 100-year lifetime incidence of AD at 72%, implying that 28% of individuals would not develop AD over any reasonable life expectancy. We confirmed the acceleration of AD onset in individuals with 1 or, especially, 2 APOE, 4 allelesbut observed no meaningful difference in 100-year lifetime incidence related to number of 4 alleles.
Conclusions The APOE 4 allele acts as a potent risk factor for AD by accelerating onset. However, the risk of AD appears heterogeneous in ways independent of APOE.Some individuals seem destined to escape AD, even over an extended lifespan. Their relative invulnerability may reflect other genes or environmental factors that can be investigated.
From Khachaturian and Associates Inc, Potomac, Md (Dr Khachaturian); Center for Epidemiologic Studies and Department of Mathematics, Utah State University, Logan (Dr Corcoran); Alzheimer's Research Center, Banner Good Samaritan Medical Center, Phoenix, Ariz (Dr Mayer); Department of Mental Health, Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, Md (Drs Mayer, Zandi, and Breitner); Geriatric Research Education and Clinical Center, Veterans Affairs Puget Sound Healthcare System, Seattle, Wash (Dr Breitner); and Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle (Dr Breitner).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues
Logroscino et al.
J. Neurol. Neurosurg. Psychiatry 2008;79:6-11.
ABSTRACT
| FULL TEXT
Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia
Goodenowe et al.
J. Lipid Res. 2007;48:2485-2498.
ABSTRACT
| FULL TEXT
Glutathione S-Transferase P1 and T1 Gene Polymorphisms Predict Longitudinal Course and Age at Onset of Alzheimer Disease
Spalletta et al.
AJGP 2007;15:879-887.
ABSTRACT
| FULL TEXT
Cognitive Domain Decline in Healthy Apolipoprotein E {varepsilon}4 Homozygotes Before the Diagnosis of Mild Cognitive Impairment
Caselli et al.
Arch Neurol 2007;64:1306-1311.
ABSTRACT
| FULL TEXT
Activation of estrogen receptor {alpha} increases and estrogen receptor beta decreases apolipoprotein E expression in hippocampus in vitro and in vivo
Wang et al.
Proc. Natl. Acad. Sci. USA 2006;103:16983-16988.
ABSTRACT
| FULL TEXT
Dementia--Epidemiological Considerations, Nomenclature, and a Tacit Consensus Definition
Breitner
J Geriatr Psychiatry Neurol 2006;19:129-136.
ABSTRACT
Time Will Be of the Essence in Treating Alzheimer Disease
Rosenberg
JAMA 2006;296:327-329.
FULL TEXT
Treating Alzheimer disease: time matters.
Rosenberg
Arch Neurol 2006;63:926-928.
FULL TEXT
Age and Apolipoprotein E*4 Allele Effects on Cerebrospinal Fluid beta-Amyloid 42 in Adults With Normal Cognition.
Peskind et al.
Arch Neurol 2006;63:936-939.
ABSTRACT
| FULL TEXT
Familial risk for Alzheimer's disease alters fMRI activation patterns
Bassett et al.
Brain 2006;129:1229-1239.
ABSTRACT
| FULL TEXT
Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease
Prohovnik et al.
Neurology 2006;66:49-55.
ABSTRACT
| FULL TEXT
Apolipoprotein E Genotype and Age-Related Myelin Breakdown in Healthy Individuals: Implications for Cognitive Decline and Dementia
Bartzokis et al.
Arch Gen Psychiatry 2006;63:63-72.
ABSTRACT
| FULL TEXT
Nature throws curveballs: APOE and nonlinear decline in Alzheimer disease
Camicioli and Kryscio
Neurology 2005;65:1855-1856.
FULL TEXT
APOE alleles predict the rate of cognitive decline in Alzheimer disease: A nonlinear model
Martins et al.
Neurology 2005;65:1888-1893.
ABSTRACT
| FULL TEXT
Predictive Utility of Apolipoprotein E Genotype for Alzheimer Disease in Outpatients With Mild Cognitive Impairment
Devanand et al.
Arch Neurol 2005;62:975-980.
ABSTRACT
| FULL TEXT
Glutathione S-Transferase P1 *C Allelic Variant Increases Susceptibility for Late-Onset Alzheimer Disease: Association Study and Relationship with Apolipoprotein E {epsilon}4 Allele
Bernardini et al.
Clin. Chem. 2005;51:944-951.
ABSTRACT
| FULL TEXT
Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease
Lane and Farlow
J. Lipid Res. 2005;46:949-968.
ABSTRACT
| FULL TEXT
Variability of Familial Risk of Alzheimer Disease Across the Late Life Span
Silverman et al.
Arch Gen Psychiatry 2005;62:565-573.
ABSTRACT
| FULL TEXT
|
